Griffiths Richard Ian 4

What Happened

• Richard Ian Griffiths, a director and 10% owner of Silence Therapeutics plc, is reported to have purchased a total of 22,000 American Depositary Shares (ADS) via two transactions: 20,000 ADS on 2025-08-03 and 2,000 ADS on 2025-10-27. Corresponding sales of the same amounts were made by Ora Capital Limited (OCL), a vehicle Griffiths controls. Prices and total dollar values are not disclosed in the filing; the transactions are reported as derivative/ADS (price listed as N/A). The filing characterizes these moves as internal transfers rather than arm’s-length market trades.

Key Details

• Transaction dates: 2025-08-03 (20,000 ADS) and 2025-10-27 (2,000 ADS). Prices: N/A in the filing.
• Nature: Reported as derivative/ADS. Footnote: each ADS is immediately convertible into 3 ordinary shares for no consideration and has no expiration date.
• Parties: Securities were sold by Ora Capital Limited (OCL) and purchased personally by Mr. Griffiths; Mr. Griffiths is a director and the controlling shareholder of OCL and disclaims beneficial ownership of OCL’s holdings except for his proportionate pecuniary interest.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing timeliness: Form 4 was filed on 2026-02-13, several months after the August and October 2025 transactions (i.e., appears late).

Context

• These entries reflect an internal reallocation from a controlled entity (OCL) to Mr. Griffiths personally rather than a clear market buy or sell that changes aggregate beneficial ownership by the Griffiths/OCL economic group. For retail investors, note that purchases reported by insiders can be informative, but here the filing and footnotes indicate no clear change in the overall economic exposure between the principal and his controlled entity.